Reunion Neuroscience, Inc.
@reunionneuro.bsky.social
Reunion is committed to innovating therapeutic solutions to treat mental health conditions through the development of novel psychedelic compounds.
www.reunionneuro.com
www.reunionneuro.com
Exciting updates from Reunion Neuroscience! Entering 2026 with momentum as we advance RE104: Phase 3 in PPD, Phase 2 in AjD & GAD. Learn more about our vision for mental health care: bit.ly/4pvVOqF
January 12, 2026 at 1:23 PM
Exciting updates from Reunion Neuroscience! Entering 2026 with momentum as we advance RE104: Phase 3 in PPD, Phase 2 in AjD & GAD. Learn more about our vision for mental health care: bit.ly/4pvVOqF
November is Lung Cancer Awareness Month. We're honoring those affected and exploring new ways to support emotional health. Our REKINDLE trial studies RE104, a psychedelic-inspired therapy for Adjustment Disorder in cancer patients. Learn more: rekindlestudies.com #LungCancerAwarenessMonth
November 3, 2025 at 2:07 PM
November is Lung Cancer Awareness Month. We're honoring those affected and exploring new ways to support emotional health. Our REKINDLE trial studies RE104, a psychedelic-inspired therapy for Adjustment Disorder in cancer patients. Learn more: rekindlestudies.com #LungCancerAwarenessMonth
It’s a time to honor the strength of those impacted by breast cancer, and to recognize that healing goes beyond the physical. Our REKINDLE Ph 2 trial is exploring RE104, a psychedelic-inspired therapeutic, for AjD in patients with cancer & other serious illnesses. REKINDLE study: rekindlestudies.com
October 17, 2025 at 12:49 PM
It’s a time to honor the strength of those impacted by breast cancer, and to recognize that healing goes beyond the physical. Our REKINDLE Ph 2 trial is exploring RE104, a psychedelic-inspired therapeutic, for AjD in patients with cancer & other serious illnesses. REKINDLE study: rekindlestudies.com
Today, we announced the dosing of the first patient in REKINDLE, our Ph 2 clinical trial evaluating RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other serious medical conditions.
Read the release: bit.ly/3KsOU6M
#psychedelictherapeutics #adjustmentdisorder
Read the release: bit.ly/3KsOU6M
#psychedelictherapeutics #adjustmentdisorder
September 30, 2025 at 12:06 PM
Today, we announced the dosing of the first patient in REKINDLE, our Ph 2 clinical trial evaluating RE104 for the treatment of adjustment disorder (AjD) in patients with cancer and other serious medical conditions.
Read the release: bit.ly/3KsOU6M
#psychedelictherapeutics #adjustmentdisorder
Read the release: bit.ly/3KsOU6M
#psychedelictherapeutics #adjustmentdisorder
Are you attending the 8th Annual Maternal Mental Health Symposium? Camille Hoffman, MD, MSCS, lead investigator in our RECONNECT trial, will be presenting clinical insights on RE104, our novel psychedelic therapy for #postpartumdepression. Registration is FREE for this virtual event!
September 22, 2025 at 5:06 PM
Are you attending the 8th Annual Maternal Mental Health Symposium? Camille Hoffman, MD, MSCS, lead investigator in our RECONNECT trial, will be presenting clinical insights on RE104, our novel psychedelic therapy for #postpartumdepression. Registration is FREE for this virtual event!
Today, we announced the final closing of our Series A Financing and shared plans to advance RE104 into clinic development for the treatment of Generalized Anxiety Disorder (GAD).
Read the full release for more specifics: bit.ly/48icPPS
#mentalhealth #clinicaldevelopment #innovation
Read the full release for more specifics: bit.ly/48icPPS
#mentalhealth #clinicaldevelopment #innovation
September 16, 2025 at 11:53 AM
Today, we announced the final closing of our Series A Financing and shared plans to advance RE104 into clinic development for the treatment of Generalized Anxiety Disorder (GAD).
Read the full release for more specifics: bit.ly/48icPPS
#mentalhealth #clinicaldevelopment #innovation
Read the full release for more specifics: bit.ly/48icPPS
#mentalhealth #clinicaldevelopment #innovation
Today, we announced positive topline results in our RECONNECT Ph 2 trial, representing a meaningful breakthrough and new hope for women with postpartum depression (#PPD). Explore the full data and outcomes in the news release: bit.ly/45Ty3lw
#postpartumdepression #maternalmentalhealth
#postpartumdepression #maternalmentalhealth
August 18, 2025 at 11:50 AM
Today, we announced positive topline results in our RECONNECT Ph 2 trial, representing a meaningful breakthrough and new hope for women with postpartum depression (#PPD). Explore the full data and outcomes in the news release: bit.ly/45Ty3lw
#postpartumdepression #maternalmentalhealth
#postpartumdepression #maternalmentalhealth
Our manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” has published in Journal of Clinical Psychopharmacology. See release news here: bit.ly/4lJJnq2
July 22, 2025 at 1:36 PM
Our manuscript entitled “Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study,” has published in Journal of Clinical Psychopharmacology. See release news here: bit.ly/4lJJnq2
The public version of the Women's Health article is here! You don't want to miss out on Lawrence Leeman, MD discussing our leading single-dose psychedelic therapy, RE104, currently being evaluated in our RECONNECT Ph 2 clinical trial for women battling #ppd. Check it out here: bit.ly/3IcmkFA
July 9, 2025 at 6:12 PM
The public version of the Women's Health article is here! You don't want to miss out on Lawrence Leeman, MD discussing our leading single-dose psychedelic therapy, RE104, currently being evaluated in our RECONNECT Ph 2 clinical trial for women battling #ppd. Check it out here: bit.ly/3IcmkFA
Thank you to Maria Shriver and the NBCNews Today Show for the opportunity to bring awareness to our new potential therapy for mothers battling #PPD. We appreciate Melissa Lavasani & Keith Heinzerling for their personal & professional contributions to this cause. View here: bit.ly/3Gc5CFB
June 25, 2025 at 9:20 PM
Thank you to Maria Shriver and the NBCNews Today Show for the opportunity to bring awareness to our new potential therapy for mothers battling #PPD. We appreciate Melissa Lavasani & Keith Heinzerling for their personal & professional contributions to this cause. View here: bit.ly/3Gc5CFB
🚨Attention🚨 Be sure to tune in to the Today Show on @NBCNews tomorrow (June 25) at 8am ET to see our interview with @Maria Shriver on #maternalmentalhealth and #postpartumdepression. See you there!
June 24, 2025 at 10:23 PM
🚨Attention🚨 Be sure to tune in to the Today Show on @NBCNews tomorrow (June 25) at 8am ET to see our interview with @Maria Shriver on #maternalmentalhealth and #postpartumdepression. See you there!
Are you attending Psychedelic Science 2025? Our SVP of Clinical Development & Regulatory Affairs, Beatrix Taylor, MSc, RAC, will be presenting an update on our RECONNECT Ph 2 study in #PPD, and the study design for our upcoming REKINDLE Ph 2 trial in #adjustment disorder. #PS2025 #PsychSci
June 11, 2025 at 1:11 PM
Are you attending Psychedelic Science 2025? Our SVP of Clinical Development & Regulatory Affairs, Beatrix Taylor, MSc, RAC, will be presenting an update on our RECONNECT Ph 2 study in #PPD, and the study design for our upcoming REKINDLE Ph 2 trial in #adjustment disorder. #PS2025 #PsychSci
Are you attending the ASCP Annual Meeting ? Our CMO, Mark Pollack, MD, will present results from our Phase 1 trial of RE104, supporting the advancement of RE104 in our Phase 2 RECONNECT and REKINDLE trials for innovative treatment in PPD and adjustment disorder. #ASCP2025 #mentalhealth
May 22, 2025 at 2:28 PM
Are you attending the ASCP Annual Meeting ? Our CMO, Mark Pollack, MD, will present results from our Phase 1 trial of RE104, supporting the advancement of RE104 in our Phase 2 RECONNECT and REKINDLE trials for innovative treatment in PPD and adjustment disorder. #ASCP2025 #mentalhealth
Big news! We have completed enrollment and dosed our last patient in our RECONNECT Phase 2 clinical trial for the treatment of #pppd, with topline results expected in Q3 2025. #maternalmentalhealth #ppd
Read more here: bit.ly/4jt37fP
Read more here: bit.ly/4jt37fP
May 19, 2025 at 1:46 PM
Big news! We have completed enrollment and dosed our last patient in our RECONNECT Phase 2 clinical trial for the treatment of #pppd, with topline results expected in Q3 2025. #maternalmentalhealth #ppd
Read more here: bit.ly/4jt37fP
Read more here: bit.ly/4jt37fP
We are featured in @womens-healthmag.bsky.social discussing our leading single-dose #psychedelic therapy, RE104, being evaluated in our RECONNECT Ph 2 clinical trial to help provide women suffering from #ppd with a potential new rapid-acting treatment solution. Full article: lnkd.in/eJb36zCn
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
May 15, 2025 at 7:58 PM
We are featured in @womens-healthmag.bsky.social discussing our leading single-dose #psychedelic therapy, RE104, being evaluated in our RECONNECT Ph 2 clinical trial to help provide women suffering from #ppd with a potential new rapid-acting treatment solution. Full article: lnkd.in/eJb36zCn
Join us at the 5th Annual Psychedelic Therapeutics & Drug Development Conference May 19-20 in San Diego! Our COO, Mark Theeuwes, will be presenting our clinical plan for the progress of our #PPD RECONNECT Ph 2 trial, and our upcoming REKINDLE Phase 2 trial for the treatment of #adjustmentdisorder.
May 7, 2025 at 1:56 PM
Join us at the 5th Annual Psychedelic Therapeutics & Drug Development Conference May 19-20 in San Diego! Our COO, Mark Theeuwes, will be presenting our clinical plan for the progress of our #PPD RECONNECT Ph 2 trial, and our upcoming REKINDLE Phase 2 trial for the treatment of #adjustmentdisorder.
Kicking off Maternal Mental Health Awareness Week, a vital reminder that too many women suffer in silence with #PPD. We are committed to changing this for women with our leading #psychedelic treatment, RE104. For more info on our RECONNECT study, visit ppdreconnectstudy.com. #MaternalMentalHealth
May 5, 2025 at 1:29 PM
Kicking off Maternal Mental Health Awareness Week, a vital reminder that too many women suffer in silence with #PPD. We are committed to changing this for women with our leading #psychedelic treatment, RE104. For more info on our RECONNECT study, visit ppdreconnectstudy.com. #MaternalMentalHealth
In a conversation with Andrea Dukakis from Colorado Public Radio, Dr. Camille Hoffman discusses postpartum depression and the use of psilocybin and shared details about our RECONNECT trial. If you'd like to listen, the discussion begins at 33:21 - bit.ly/3GAXQ7S
May 1, 2025 at 2:29 PM
In a conversation with Andrea Dukakis from Colorado Public Radio, Dr. Camille Hoffman discusses postpartum depression and the use of psilocybin and shared details about our RECONNECT trial. If you'd like to listen, the discussion begins at 33:21 - bit.ly/3GAXQ7S
Brian Barnett, MD, from the Cleveland Clinic spoke with Cleveland.com about the use of synthetic psychedelics for women suffering from PPD, and how our RE104 treatment is currently being evaluated at the Clinic's trial site. Learn more about our RECONNECT trial & enrollment: bit.ly/42vwIQn
April 29, 2025 at 1:12 PM
Brian Barnett, MD, from the Cleveland Clinic spoke with Cleveland.com about the use of synthetic psychedelics for women suffering from PPD, and how our RE104 treatment is currently being evaluated at the Clinic's trial site. Learn more about our RECONNECT trial & enrollment: bit.ly/42vwIQn
In the “We Are More Than Moms: Unfiltered” podcast, @melissalavasani.bsky.social, a mother of two, shares her powerful journey with postpartum depression and how psychedelics became a turning point in her healing. Thank you for sharing your story, Melissa. Listen to the episode here: bit.ly/3EBa6EU
Psychedelics for postpartum depression with Melissa Lavasani | We Are More Than Moms
bit.ly
April 24, 2025 at 2:45 PM
In the “We Are More Than Moms: Unfiltered” podcast, @melissalavasani.bsky.social, a mother of two, shares her powerful journey with postpartum depression and how psychedelics became a turning point in her healing. Thank you for sharing your story, Melissa. Listen to the episode here: bit.ly/3EBa6EU
Still relevant. Still important. We’re resurfacing this Patient Safety & Quality Healthcare article by Dr. Sheryl Kingsberg on new progress in treating postpartum depression to keep the conversation going and highlight our current RECONNECT study. Read it here: bit.ly/3YWUfaY
April 22, 2025 at 5:43 PM
Still relevant. Still important. We’re resurfacing this Patient Safety & Quality Healthcare article by Dr. Sheryl Kingsberg on new progress in treating postpartum depression to keep the conversation going and highlight our current RECONNECT study. Read it here: bit.ly/3YWUfaY
In case you missed it, Jeffrey Newport, MD, chatted with Trevor Scott on CBS Austin's 'We Are Austin' (KEYE-TV) about our RECONNECT study a few weeks ago. Here is a behind the scene image, and be sure to watch the great (and informative) interview here: bit.ly/3QYCsvc
April 16, 2025 at 1:27 PM
In case you missed it, Jeffrey Newport, MD, chatted with Trevor Scott on CBS Austin's 'We Are Austin' (KEYE-TV) about our RECONNECT study a few weeks ago. Here is a behind the scene image, and be sure to watch the great (and informative) interview here: bit.ly/3QYCsvc
In Hatch Magazine, Melissa Lavasani shares why traditional treatments often fall short for moms facing #PPD, and how our rapid-acting #psychedelic therapy in the RECONNECT study (ppdreconnectstudy.com) has the potential to change the future of #maternalmentalhealth.
Read here: bit.ly/4lrYowY
Read here: bit.ly/4lrYowY
April 14, 2025 at 1:20 PM
In Hatch Magazine, Melissa Lavasani shares why traditional treatments often fall short for moms facing #PPD, and how our rapid-acting #psychedelic therapy in the RECONNECT study (ppdreconnectstudy.com) has the potential to change the future of #maternalmentalhealth.
Read here: bit.ly/4lrYowY
Read here: bit.ly/4lrYowY
If you haven't listened to it yet, check out our President & CEO, Greg Mayes, on the Empowered Patient Podcast with Karen Jagoda. He dives into Reunion’s work developing #psychedelic therapy for rapid #postpartumdepression. Listen now: bit.ly/3BDKHJb
#maternalmentalhealth #RECONNECTstudy #PPD
#maternalmentalhealth #RECONNECTstudy #PPD
Empowered Patient Podcast: Developing Psychedelic Therapy for Rapid Improvement of Postpartum Depression with Greg Mayes Reunion Neuroscience
Greg Mayes, President and CEO of Reunion Neuroscience, is developing a psychedelic therapy for the treatment of postpartum depression. This serious acute, non-chronic mental health condition affe...
bit.ly
April 9, 2025 at 3:14 PM
If you haven't listened to it yet, check out our President & CEO, Greg Mayes, on the Empowered Patient Podcast with Karen Jagoda. He dives into Reunion’s work developing #psychedelic therapy for rapid #postpartumdepression. Listen now: bit.ly/3BDKHJb
#maternalmentalhealth #RECONNECTstudy #PPD
#maternalmentalhealth #RECONNECTstudy #PPD
At the ADAA 2025 Conference April 3-5, we presented our study design for the REKINDLE Ph 2 clinical trial evaluating our leading #psychedelic candidate, RE104, for the treatment of Adjustment Disorder (AjD) in patients with cancer & other medical illnesses. See our release news here: bit.ly/4cqdrDp
April 7, 2025 at 1:39 PM
At the ADAA 2025 Conference April 3-5, we presented our study design for the REKINDLE Ph 2 clinical trial evaluating our leading #psychedelic candidate, RE104, for the treatment of Adjustment Disorder (AjD) in patients with cancer & other medical illnesses. See our release news here: bit.ly/4cqdrDp